Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2871571 | The Annals of Thoracic Surgery | 2016 | 8 Pages |
Abstract
TAVR was associated with greater total costs and mortality compared with SAVR in intermediate-risk and high-risk patients while conferring lower major morbidity and improved resource use. Increased cost of TAVR appears largely related to the cost of the valve. Until the price of TAVR valves decreases, these data suggest that TAVR may not provide the most cost-effective strategy, particularly for intermediate-risk patients.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Gorav MD, Damien J. MD, MS, Alan M. MD, Ravi K. MD, Leora T. MD, Ivan K. MD, D. Scott MD, Mohammed A. MD, Jeffrey B. MD,